Sex as a Biological Variable Supplement - Host Response Mediators in Coronavirus (COVID-19) Infection
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: Supplement to P00168
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$37,449Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
University of British ColumbiaResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The coronavirus (COVID-19) epidemic continues to grow exponentially affecting over 71,429 individuals with 1775 deaths (February 17, 2020), mostly in China but also in other countries. WHO and others are launching clinical trials of novel anti-virals. We have a unique opportunity to complement trials of anti-virals with investigation of modulation of the human host response to improve outcomes of COVID-19. We are proposing to "repurpose" a class of drugs (ARBs) for hypertension (high blood pressure) that have been shown to prevent lung injury in influenza and could work on corona because influenza and coronavirus bind to the same cell receptor in the lung. ARBs are commonly prescribed for high blood pressure (50-70% of patients). To date, there have been no clinical studies of ARBs in COVID-19. We call our study ARBs CORONA. We believe that ARBs can decrease the severity of COVID-19 and mortality of hospitalized COVID-19 infected adults. We will evaluate safety and effectiveness of available ARBs in COVID-19 in a multicentre study of 497 hospitalized adult patients who are or are not already on ARBs. Key personnel are in place to expedite this study. If this study is successful, ARBs can potentially limit complications and mortality of COVID-19. Potential results: ARBs are inexpensive clinically available cardiovascular drugs. If this study is successful, ARBs can potentially be used globally to limit complications and death due to COVID-19.